A Phase I/II Multicenter, Open-Label Study of Lu-177-αvβ3-IAC, for the Treatment of Angiogenic Breast Cancer Patients.
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer Stage IV
Interventions: DRUG: Lutetium-177-DOTAGA-PEG-IAC
Sponsor: Advanced Imaging Projects, LLC
Collaborators: All India Institute of Medical Sciences, New Delhi|University of Witwatersrand, South Africa|Postgraduate Institute of Medical and Research|US Department of Veterans Affairs